{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:05:22Z","timestamp":1790301922457,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bcp.2017.10.002","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T20:33:23Z","timestamp":1507667603000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties"],"prefix":"10.1016","volume":"146","author":[{"given":"Finbarr P.M.","family":"O'Harte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadivel","family":"Parthsarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.10.002_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semnephrol.2012.12.008","article-title":"The adipose tissue as an endocrine organ","volume":"33","author":"Adamczak","year":"2013","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.bcp.2017.10.002_b0015","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1210\/en.2004-1427","article-title":"Apelin, a newly identified adipokine up-regulated by insulin and obesity","volume":"146","author":"Boucher","year":"2005","journal-title":"Endocrinology."},{"key":"10.1016\/j.bcp.2017.10.002_b0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","article-title":"Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist","volume":"65","author":"Brame","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.bcp.2017.10.002_b0030","doi-asserted-by":"crossref","first-page":"e51236","DOI":"10.1371\/journal.pone.0051236","article-title":"Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus","volume":"7","author":"Cavallo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2017.10.002_b0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/17460441.2011.571251","article-title":"Update on apelin peptides as putative targets for cardiovascular drug discovery","volume":"6","author":"Charles","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"issue":"Pt B","key":"10.1016\/j.bcp.2017.10.002_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2015.05.017","article-title":"Apelin receptors: from signaling to antidiabetic strategy","volume":"763","author":"Chaves-Almagro","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2017.10.002_b0045","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2165\/11201060-000000000-00000","article-title":"Liraglutide: a review of its use in type 2 diabetes mellitus","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs."},{"key":"10.1016\/j.bcp.2017.10.002_b0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1573399810666140825154815","article-title":"Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus","volume":"10","author":"Choudhury","year":"2014","journal-title":"Curr Diabetes Rev."},{"key":"10.1016\/j.bcp.2017.10.002_b0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","volume":"2","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bcp.2017.10.002_b0060","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8227(11)70014-6","article-title":"Insulin effects in muscle and adipose tissue","volume":"93","author":"Dimitriadis","year":"2011","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.bcp.2017.10.002_b0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cmet.2008.10.003","article-title":"Apelin stimulates glucose utilization in normal and obese insulin-resistant mice","volume":"28","author":"Dray","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2017.10.002_b0070","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1471-4159.2004.02591.x","article-title":"Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure","volume":"90","author":"El Messari","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2017.10.002_b0075","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1021\/bi030049s","article-title":"Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 co-receptor","volume":"42","author":"Fan","year":"2003","journal-title":"APJ. Biochemistry."},{"key":"10.1016\/j.bcp.2017.10.002_b0080","first-page":"883","article-title":"Central apelin-13 administration modulates hypothalamic control of feeding","volume":"30","author":"Ferrante","year":"2016","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"10.1016\/j.bcp.2017.10.002_b0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00252768","article-title":"Abnormal plasma glucose and insulin responses in heterozygous lean (ob\/+) mice","volume":"20","author":"Flatt","year":"1981","journal-title":"Diabetologia."},{"key":"10.1016\/j.bcp.2017.10.002_b0090","first-page":"265","article-title":"Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1\u201330) and GIP(1\u201342) in high-fat fed mice","volume":"208","author":"Gault","year":"2011","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2017.10.002_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1042\/CS20110006","article-title":"Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity","volume":"121","author":"Gault","year":"2011","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.bcp.2017.10.002_b0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00007890-198510000-00018","article-title":"An improved method for isolation of mouse pancreatic islets","volume":"40","author":"Gotoh","year":"1985","journal-title":"Transplantation."},{"key":"10.1016\/j.bcp.2017.10.002_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13679-015-0155-x","article-title":"Weight Loss and the prevention and treatment of Type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action","volume":"4","author":"Grams","year":"2015","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.bcp.2017.10.002_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1381612043382774","article-title":"Structurally modified analogues of glucagon-like Peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents","volume":"10","author":"Green","year":"2004","journal-title":"Curr. Pharmaceutical Design."},{"key":"10.1016\/j.bcp.2017.10.002_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.metabol.2003.09.015","article-title":"Lys9 for Glu9 substitution in glucagon-like peptide-1(7\u201336)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9\u201336)amide and exendin (9\u201339)","volume":"53","author":"Green","year":"2004","journal-title":"Metabolism."},{"key":"10.1016\/j.bcp.2017.10.002_b0120","article-title":"Targeting Apelinergic System in Cardiometabolic Disease","author":"Guo","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bcp.2017.10.002_b0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/cen.12404","article-title":"Circulating apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control","volume":"81","author":"Habchi","year":"2014","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.bcp.2017.10.002_b0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.regpep.2005.05.003","article-title":"Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding","volume":"130","author":"Heinonen","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.bcp.2017.10.002_b0135","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2017.10.002_b0140","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/en.2006-1270","article-title":"Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice","volume":"148","author":"Higuchi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2017.10.002_b0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2016.07.012","article-title":"Apelin\/APJ system as a therapeutic target in diabetes and its complications","volume":"119","author":"Hu","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcp.2017.10.002_b0150","article-title":"Development of Potent and Metabolically Stable APJ Ligands with High Therapeutic Potential","author":"Juhl","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bcp.2017.10.002_b0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1017\/S0007114509991577","article-title":"Terminalia bellirica stimulates the secretion and action of insulin and inhibits starch digestion and protein glycation in vitro","volume":"103","author":"Kasabri","year":"2010","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.bcp.2017.10.002_b0160","first-page":"1481","article-title":"Lambeir A and DeMeester I (2016) Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme","volume":"11","author":"Kehoe","year":"1864","journal-title":"Biochimi et biophys acta."},{"key":"10.1016\/j.bcp.2017.10.002_b0165","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.bcp.2009.05.037","article-title":"Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties","volume":"78","author":"Kerr","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.10.002_b0170","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bcp.2010.04.021","article-title":"Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1","volume":"80","author":"Kerr","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.10.002_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000348667","article-title":"Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity","volume":"6","author":"Krist","year":"2013","journal-title":"Obes. Facts."},{"key":"10.1016\/j.bcp.2017.10.002_b0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1471-4159.2000.0740034.x","article-title":"Characterization of apelin, the ligand for the APJ receptor","volume":"74","author":"Lee","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2017.10.002_b0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/en.2004-0359","article-title":"Modification of the terminal residue of apelin-13 antagonizes its hypotensive action","volume":"146","author":"Lee","year":"2005","journal-title":"Endocrinology."},{"key":"10.1016\/j.bcp.2017.10.002_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.201200409","article-title":"(Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and bcell function in high-fat-fed mice","volume":"8","author":"Lennox","year":"2013","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bcp.2017.10.002_b0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrm3351","article-title":"Regulation of glucose transport by insulin: traffic control of GLUT4","volume":"13","author":"Leto","year":"2012","journal-title":"Nat. Rev. Molec. Cell Biol."},{"key":"10.1016\/j.bcp.2017.10.002_b0200","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-2006-948309","article-title":"Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects","volume":"114","author":"Li","year":"2006","journal-title":"Exp. Clin. Endocrinol. Diabetes."},{"key":"10.1016\/j.bcp.2017.10.002_b0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.peptides.2011.11.011","article-title":"Central apelin-13 inhibits food intake via the CRF receptor in mice","volume":"33","author":"Lv","year":"2012","journal-title":"Peptides."},{"key":"10.1016\/j.bcp.2017.10.002_b0210","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1046\/j.1471-4159.2003.01587.x","article-title":"Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin","volume":"84","author":"Medhurst","year":"2003","journal-title":"J Neurochem."},{"key":"10.1016\/j.bcp.2017.10.002_b0215","doi-asserted-by":"crossref","DOI":"10.2337\/diab.45.8.1132","article-title":"Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion","volume":"45","author":"McClenaghan","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2017.10.002_b0220","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bph.12356","article-title":"Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice","volume":"170","author":"McKillop","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2017.10.002_b0225","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1021\/acs.jmedchem.7b00723","article-title":"Synthetic Modification within the \u201cRPRL\u201d Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation","volume":"60","author":"McKinnie","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.10.002_b0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ceca.2003.11.007","article-title":"Time-correlation between membrane depolarization and intracellular calcium in insulin secreting BRIN-BD11 cells: studies using FLIPR","volume":"36","author":"Miguel","year":"2004","journal-title":"Cell Calcium"},{"key":"10.1016\/j.bcp.2017.10.002_b0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/bip.22498","article-title":"Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid","volume":"102","author":"Murza","year":"2014","journal-title":"Biopolymers."},{"key":"10.1016\/j.bcp.2017.10.002_b0240","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1021\/jm501916k","article-title":"C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action","volume":"58","author":"Murza","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.10.002_b0245","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/JOE-13-0227","article-title":"The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis","volume":"219","author":"O'Carroll","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2017.10.002_b0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0378-1119(93)90495-O","article-title":"A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11","volume":"136","author":"O'Dowd","year":"1993","journal-title":"Gene"},{"key":"10.1016\/j.bcp.2017.10.002_b0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.bcp.2017.10.002_b0260","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/diabetes.47.10.1619","article-title":"Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation","volume":"47","author":"O'Harte","year":"1998","journal-title":"Diabetes."},{"key":"10.1016\/j.bcp.2017.10.002_b0265","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0167-0115(00)00125-7","article-title":"Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7\u201336)amide in obese diabetic ob\/ob mice","volume":"96","author":"O'Harte","year":"2001","journal-title":"Regul Pept."},{"key":"10.1016\/j.bcp.2017.10.002_b0270","article-title":"Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice","author":"Parthsarathy","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2017.10.002_b0275","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/dom.12713","article-title":"Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet induced obese diabetic mice","volume":"18","author":"O'Harte","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.bcp.2017.10.002_b0280","doi-asserted-by":"crossref","first-page":"E58784","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2017.10.002_b0285","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbagen.2016.01.015","article-title":"A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties","volume":"1860","author":"Parthsarathy","year":"2016","journal-title":"Biochim Biophys Acta."},{"issue":"66","key":"10.1016\/j.bcp.2017.10.002_b0290","first-page":"102","article-title":"Stable analogues of apelin-13 exhibit enhanced satiety in normal mice compared to the GLP-1 mimetic exendin-4","volume":"34","author":"Parthsarathy","year":"2017","journal-title":"Diabetic Med."},{"key":"10.1016\/j.bcp.2017.10.002_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2014.10.025","article-title":"Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice","volume":"401","author":"Pathak","year":"2015","journal-title":"Mol Cell Endocrinol."},{"key":"10.1016\/j.bcp.2017.10.002_b0300","series-title":"R1A and Related Procedures in Medicine","first-page":"161","article-title":"Radioiodination of proteins with the Iodogen method","author":"Paus","year":"1982"},{"key":"10.1016\/j.bcp.2017.10.002_b0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/pr.110.002949","article-title":"International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function","volume":"62","author":"Pitkin","year":"2010","journal-title":"Pharmacological Rev."},{"key":"10.1016\/j.bcp.2017.10.002_b0310","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.peptides.2011.12.005","article-title":"Central and peripheral apelin receptor distribution in the mouse: species differences with rat","volume":"33","author":"Pope","year":"2012","journal-title":"Peptides."},{"key":"10.1016\/j.bcp.2017.10.002_b0315","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.regpep.2010.03.005","article-title":"Apelin is a novel islet peptide","volume":"162","author":"Ringstr\u00f6m","year":"2010","journal-title":"Regul Pept."},{"key":"10.1016\/j.bcp.2017.10.002_b0320","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.3390\/ijms140510497","article-title":"Obesity-associated oxidative stress: strategies finalized to improve redox state","volume":"14","author":"Savini","year":"2013","journal-title":"Int J Mol Sci."},{"issue":"6","key":"10.1016\/j.bcp.2017.10.002_b0325","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/14779072.2014.911661","article-title":"Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy","volume":"12","author":"Scimia","year":"2014","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.bcp.2017.10.002_b0330","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1592\/phco.31.9.896","article-title":"Liraglutide: clinical pharmacology and considerations for therapy","volume":"31","author":"Sisson","year":"2011","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.bcp.2017.10.002_b0335","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2005.05.004","article-title":"The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice","volume":"131","author":"S\u00f6rhede Winzell","year":"2005","journal-title":"Regul Pept."},{"key":"10.1016\/j.bcp.2017.10.002_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00351-3","article-title":"Intracerebroventricular injection of apelin-13 reduces food intake in the rat","volume":"353","author":"Sunter","year":"2003","journal-title":"Neurosci Lett."},{"key":"10.1016\/j.bcp.2017.10.002_b0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.0000033522.37861.69","article-title":"Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility","volume":"91","author":"Szokodi","year":"2002","journal-title":"Circ Res."},{"key":"10.1016\/j.bcp.2017.10.002_b0350","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1006\/bbrc.2002.6575","article-title":"The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats","volume":"291","author":"Taheri","year":"2002","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.bcp.2017.10.002_b0355","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","article-title":"Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor","volume":"251","author":"Tatemoto","year":"1998","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.bcp.2017.10.002_b0360","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0167-0115(01)00236-1","article-title":"The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism","volume":"99","author":"Tatemoto","year":"2001","journal-title":"Regul Pept."},{"key":"10.1016\/j.bcp.2017.10.002_b0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/13813455.2016.1211709","article-title":"Effects of apelin on reproductive functions: relationship with feeding behavior and energy metabolism","volume":"123","author":"Tekin","year":"2017","journal-title":"Arch Physiol Biochem."},{"key":"10.1016\/j.bcp.2017.10.002_b0370","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4239\/wjd.v8.i4.120","article-title":"Type 2 diabetes and quality of life","volume":"8","author":"Trikkalinou","year":"2017","journal-title":"World J Diabetes."},{"key":"10.1016\/j.bcp.2017.10.002_b0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1677\/JOE-10-0085","article-title":"Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety","volume":"207","author":"Taylor","year":"2010","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2017.10.002_b0380","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2826.2007.01617.x","article-title":"Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL\/6 mice","volume":"20","author":"Valle","year":"2008","journal-title":"J Neuroendocrinol."},{"key":"10.1016\/j.bcp.2017.10.002_b0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12079-012-0188-9","article-title":"Novel method to differentiate 3T3 L1 cells in vitro to produce highly sensitive adipocytes for a GLUT4 mediated glucose uptake using fluorescent glucose analog","volume":"7","author":"Vishwanath","year":"2013","journal-title":"J. Cell Commun Signaling."},{"key":"10.1016\/j.bcp.2017.10.002_b0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.peptides.2013.08.005","article-title":"Apelin stimulates both cholecystokinin and glucagon-like peptide 1 secretions in vitro and in vivo in rodents","volume":"48","author":"Wattez","year":"2013","journal-title":"Peptides."},{"key":"10.1016\/j.bcp.2017.10.002_b0395","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1464-5491.2007.02186.x","article-title":"The importance of free fatty acids in the development of Type 2 diabetes","volume":"24","author":"Wilding","year":"2007","journal-title":"Diabet Med."},{"key":"10.1016\/j.bcp.2017.10.002_b0400","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.peptides.2012.08.004","article-title":"In vivo, ex vivo, and in vitro studies on apelin's effect on myocardial glucose uptake","volume":"37","author":"Xu","year":"2012","journal-title":"Peptides."},{"key":"10.1016\/j.bcp.2017.10.002_b0405","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1152\/ajpendo.00385.2009","article-title":"Apelin is necessary for the maintenance of insulin sensitivity","volume":"298","author":"Yue","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2017.10.002_b0410","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.bmc.2014.04.001","article-title":"Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structure-activity","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2017.10.002_b0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11010-011-0799-0","article-title":"Apelin stimulates glucose uptake through the PI3K\/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes","volume":"353","author":"Zhu","year":"2011","journal-title":"Mol. Cell. Biochem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217306160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217306160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:12:24Z","timestamp":1719508344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217306160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":81,"alternative-id":["S0006295217306160"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.10.002","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}